Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Trading Down 2.3 %

Galmed Pharmaceuticals stock opened at $2.56 on Friday. The firm’s fifty day moving average price is $2.90 and its two-hundred day moving average price is $3.64. The firm has a market capitalization of $1.64 million, a price-to-earnings ratio of -0.15 and a beta of 0.66. Galmed Pharmaceuticals has a 1-year low of $2.23 and a 1-year high of $23.80.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is currently owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.